IBERE PHARMACEUTICALS

Ibere Pharmaceuticals Acquisition Corp. (Nasdaq: IBER) is a blank-check company formed to pursue a business combination in the pharmaceutical and life sciences sector. The company filed a Form 10-Q with the SEC on November 14, 2022, covering the quarterly period ended September 30, 2022, with accession number 0001410578-22-003339. IBER completed its initial public offering in 2021 and, as of the filing date, remained in the search phase for a suitable acquisition target within the biopharma and healthcare space. The company operates as a special purpose acquisition vehicle, with its management team focused on identifying merger candidates across the pharmaceutical industry. Visit SpacDesk and sign up for full access to IBER's filing history, deal timelines, and comprehensive SPAC analytics.